Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2008

Trubion Pharmaceuticals and Wyeth Lengthen Collaboration

  • Wyeth Pharmaceuticals has decided to extend its research collaboration with Trubion Pharmaceuticals for an additional year. For these additional research services, Trubion will receive approximately $3.2 million.

    The original agreement between the two companies was inked in December 2005 for the development and worldwide commercialization of TRU-015, Trubion’s lead product that is currently in Phase II development for the treatment of rheumatoid arthritis, and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20.

    Related Links:

    Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »